A Brain-Penetrant MET Inhibitor Achieves Responses in Glioblastoma

Cancer Discovery- United States

doi 10.1158/2159-8290.cd-rw2018-186

Full Text

Abstract

Available in

Categories

Date

October 26, 2018

Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

A Brain Penetrant Mutant IDH1 Inhibitor Provides in Vivo Survival Benefit

Scientific Reports

Multidisciplinary

Breton

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate

English

Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor

Molecular Biology

English

The Brain-Penetrant Clinical ATM Inhibitor AZD1390 Radiosensitizes and Improves Survival of Preclinical Brain Tumor Models

Science advances

Multidisciplinary

English

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR

English

Nivolumab Plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors

Cancer Discovery

English

An Orally Bioavailable C-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth

Anti-Cancer Agents in Medicinal Chemistry

Cancer Research

Molecular Medicine

English

Inhibition of EGFR Induces a C-Met-Driven Stem Cell Population in Glioblastoma

Molecular Medicine

Developmental Biology

English

Fatal Measles Virus Infection Prevented by Brain-Penetrant Fusion Inhibitors

Journal of Virology

English